Pharmacyclics Inc. (PCYC) reported that its first-quarter GAAP net income was $75.6 million, or $1.02 per share, compared to GAAP net loss of $14.5 million, or $0.21 loss per share in the year ago quarter.
The non-GAAP net income for the fiscal quarter was $78.8 million or $1.06 income per share, compared to a non-GAAP net loss of $12.4 million, or $0.18 per share last year.
Revenue for the quarter was $102.7 million, compared to $37,000 last year, an increase of approximately $102.7 million.
Revenue for the latest quarter consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement with Janssen Biotech, Inc.
Analysts polled by Thomson Reuters expected the company to report earnings of $0.75 per share on revenues of $87.64 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.